Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

(2016) Yuka Miyoshi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

(2015) Juan Martin-Liberal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Response to Comment on Hughes et al. An Early Pregnancy HbA1c≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care 2014;37:2953–2959

(2015) Ruth C.E. Hughes et al.   DIABETES CARE

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

(2015) Caroline Gaudy et al.   DIABETES CARE

Toxicity Patterns With Immunomodulating Antibodies and Their Combinations

(2015) John B.A.G. Haanen et al.   SEMINARS IN ONCOLOGY

Role of immune system in type 1 diabetes mellitus pathogenesis

(2014) Leszek Szablewski   INTERNATIONAL IMMUNOPHARMACOLOGY

Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease

(2014) Majid Jaberi-Douraki et al.   PEDIATRIC DIABETES

Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes

(2014) Nora M. Kochupurakkal et al.   PLoS One

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease

(2012) F. Torino et al.   ONCOLOGIST

Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)

(2012) Akihisa Imagawa et al.   Journal of Diabetes Investigation

Genetics of the HLA Region in the Prediction of Type 1 Diabetes

(2011) Janelle A. Noble et al.   Current Diabetes Reports

Opportunistic autoimmune disorders

(2010) Yi-chi M. Kong et al.   Annals of the New York Academy of Sciences

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes

(2009) Scherezade Momin et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families

(2008) H. Erlich et al.   DIABETES

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS